S 146
118th Congress
Senate
Health
Digestive and metabolic diseases
Drug therapy
Employee benefits and pensions
Health care costs and insurance
Health care coverage and access
Medicare
Prescription drugs
Cap Insulin Prices Act
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 12, 2024
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.
Jan 30, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jan 30, 2023
Introduced in Senate
Plain-English summary
Cap Insulin Prices Act
This bill reduces cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.
Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $25 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2024.
The bill caps cost-sharing under the Medicare prescription drug benefit for a month's supply insulin products at $25 beginning in 2024. The current cap on insulin products under Medicare is $35 per month.
What's happening now
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.
Committees of jurisdiction
2
Cosponsors
1